PROMINENT
Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in diabetic patients
- Stage
- klaar
- Medicine
- pemafibrate
- Population
- Diabetes Mellitus
- Phase
- III
- First Patient In
- 28 August 2017
- Last Patient In
- 20 March 2020
- Last Patient Last Visit
- 18 June 2022
National Lead
prof. dr. F.L.J. Visseren
Study Director
prof. dr. F.M.A.C. Martens
Cardioloog
Office Contact
